PharmaDirections appreciated Orexigen Therapeutics on receiving the FDA Advisory Board approval for their anti-obesity drug Contrave.

PharmaDirections claims it to be a proud moment with regard to Orexigen's pharmaceutical development partner and at the same time seemingly has developed and produced the first ContraveT product that completes an entire clinical development.

Orexigen achieved a major breakthrough in case of the two out of three Americans who are overweight or obese.

It seemingly is the all new technique to cut down weight which has been launched in the last 10 years and several drugs giving the same effects have been pulled off due to safety concerns. Two other drug manufacturers filed their NDA applications for anti-obesity cures in the start of the year, but a similar advisory panel that gave a nod for ContraveT denied their applications due to side effects.

ContraveT amalgamates the anti-craving drug naltrexone along with the antidepressant bupropion in a single tablet. The so called mixture further aides in boosting the complete metabolism while consuming up on the appetite and cravings.

PharmaDirections is responsible for developing innovative formulations which yields a tri-layer tablet that aid in regulation of naltrexone independent from the controlled release of bupropion.

PharmaDirections at the same time has released intellectual property that seeks for cutting back on the side effects and at the same time offering unique pharmacokinetic parameters. Making use of pharmacokinetic modeling which were seen in case of pharmacokinetic/pharmacodynamic associations that permitted the lowering of naltrexone dose from 50 mgs in the single use tablet to 8 mgs in the combination product.